Cargando…

The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review

OBJECTIVES: To review studies on the cost consequences of compliance and/or persistence in cardiovascular disease (CVD) and related conditions (hypertension, dyslipidaemia, diabetes and heart failure) published since 1995, and to evaluate the effects of noncompliance on healthcare expenditure and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Muszbek, N, Brixner, D, Benedict, A, Keskinaslan, A, Khan, Z M
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2325652/
https://www.ncbi.nlm.nih.gov/pubmed/18199282
http://dx.doi.org/10.1111/j.1742-1241.2007.01683.x
_version_ 1782152731327201280
author Muszbek, N
Brixner, D
Benedict, A
Keskinaslan, A
Khan, Z M
author_facet Muszbek, N
Brixner, D
Benedict, A
Keskinaslan, A
Khan, Z M
author_sort Muszbek, N
collection PubMed
description OBJECTIVES: To review studies on the cost consequences of compliance and/or persistence in cardiovascular disease (CVD) and related conditions (hypertension, dyslipidaemia, diabetes and heart failure) published since 1995, and to evaluate the effects of noncompliance on healthcare expenditure and the cost-effectiveness of pharmaceutical interventions. METHODS: English language papers published between January 1995 and February 2007 that examined compliance/persistence with medication for CVD or related conditions, provided an economic evaluation of pharmacological interventions or cost analysis, and quantified the cost consequences of noncompliance, were identified through database searches. The cost consequences of noncompliance were compared across studies descriptively. RESULTS: Of the 23 studies identified, 10 focused on hypertension, seven on diabetes, one on dyslipidaemia, one on coronary heart disease, one on heart failure and three covered multiple diseases. In studies assessing drug costs only, increased compliance/persistence led to increased drug costs. However, increased compliance/persistence increased the effectiveness of treatment, leading to a decrease in medical events and non-drug costs. This offset the higher drug costs, leading to savings in overall treatment costs. In studies evaluating the effect of compliance/persistence on the cost-effectiveness of pharmacological interventions, increased compliance/persistence appeared to reduce cost-effectiveness ratios, but the extent of this effect was not quantified. CONCLUSIONS: Noncompliance with cardiovascular and antidiabetic medication is a significant problem. Increased compliance/persistence leads to increased drug costs, but these are offset by reduced non-drug costs, leading to overall cost savings. The effect of noncompliance on the cost-effectiveness of pharmacological interventions is inconclusive and further research is needed to resolve the issue.
format Text
id pubmed-2325652
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-23256522008-04-28 The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review Muszbek, N Brixner, D Benedict, A Keskinaslan, A Khan, Z M Int J Clin Pract Late Breaker OBJECTIVES: To review studies on the cost consequences of compliance and/or persistence in cardiovascular disease (CVD) and related conditions (hypertension, dyslipidaemia, diabetes and heart failure) published since 1995, and to evaluate the effects of noncompliance on healthcare expenditure and the cost-effectiveness of pharmaceutical interventions. METHODS: English language papers published between January 1995 and February 2007 that examined compliance/persistence with medication for CVD or related conditions, provided an economic evaluation of pharmacological interventions or cost analysis, and quantified the cost consequences of noncompliance, were identified through database searches. The cost consequences of noncompliance were compared across studies descriptively. RESULTS: Of the 23 studies identified, 10 focused on hypertension, seven on diabetes, one on dyslipidaemia, one on coronary heart disease, one on heart failure and three covered multiple diseases. In studies assessing drug costs only, increased compliance/persistence led to increased drug costs. However, increased compliance/persistence increased the effectiveness of treatment, leading to a decrease in medical events and non-drug costs. This offset the higher drug costs, leading to savings in overall treatment costs. In studies evaluating the effect of compliance/persistence on the cost-effectiveness of pharmacological interventions, increased compliance/persistence appeared to reduce cost-effectiveness ratios, but the extent of this effect was not quantified. CONCLUSIONS: Noncompliance with cardiovascular and antidiabetic medication is a significant problem. Increased compliance/persistence leads to increased drug costs, but these are offset by reduced non-drug costs, leading to overall cost savings. The effect of noncompliance on the cost-effectiveness of pharmacological interventions is inconclusive and further research is needed to resolve the issue. Blackwell Publishing Ltd 2008-02-01 /pmc/articles/PMC2325652/ /pubmed/18199282 http://dx.doi.org/10.1111/j.1742-1241.2007.01683.x Text en © 2008 The Authors Journal compilation © 2008 Blackwell Publishing Ltd https://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Late Breaker
Muszbek, N
Brixner, D
Benedict, A
Keskinaslan, A
Khan, Z M
The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review
title The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review
title_full The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review
title_fullStr The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review
title_full_unstemmed The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review
title_short The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review
title_sort economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review
topic Late Breaker
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2325652/
https://www.ncbi.nlm.nih.gov/pubmed/18199282
http://dx.doi.org/10.1111/j.1742-1241.2007.01683.x
work_keys_str_mv AT muszbekn theeconomicconsequencesofnoncomplianceincardiovasculardiseaseandrelatedconditionsaliteraturereview
AT brixnerd theeconomicconsequencesofnoncomplianceincardiovasculardiseaseandrelatedconditionsaliteraturereview
AT benedicta theeconomicconsequencesofnoncomplianceincardiovasculardiseaseandrelatedconditionsaliteraturereview
AT keskinaslana theeconomicconsequencesofnoncomplianceincardiovasculardiseaseandrelatedconditionsaliteraturereview
AT khanzm theeconomicconsequencesofnoncomplianceincardiovasculardiseaseandrelatedconditionsaliteraturereview
AT muszbekn economicconsequencesofnoncomplianceincardiovasculardiseaseandrelatedconditionsaliteraturereview
AT brixnerd economicconsequencesofnoncomplianceincardiovasculardiseaseandrelatedconditionsaliteraturereview
AT benedicta economicconsequencesofnoncomplianceincardiovasculardiseaseandrelatedconditionsaliteraturereview
AT keskinaslana economicconsequencesofnoncomplianceincardiovasculardiseaseandrelatedconditionsaliteraturereview
AT khanzm economicconsequencesofnoncomplianceincardiovasculardiseaseandrelatedconditionsaliteraturereview